These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27757701)

  • 1. Young patients and those with a low eGFR benefitted more from denosumab therapy in femoral neck bone mineral density.
    Cheng BC; Chen YC
    Clin Rheumatol; 2017 Apr; 36(4):929-932. PubMed ID: 27757701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.
    Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
    Osteoporos Int; 2019 Jan; 30(1):241-249. PubMed ID: 30187112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.
    Langdahl BL; Teglbjærg CS; Ho PR; Chapurlat R; Czerwinski E; Kendler DL; Reginster JY; Kivitz A; Lewiecki EM; Miller PD; Bolognese MA; McClung MR; Bone HG; Ljunggren Ö; Abrahamsen B; Gruntmanis U; Yang YC; Wagman RB; Mirza F; Siddhanti S; Orwoll E
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1335-42. PubMed ID: 25607608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
    Lyu H; Zhao SS; Yoshida K; Tedeschi SK; Xu C; Nigwekar SU; Leder BZ; Solomon DH
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5611-5620. PubMed ID: 31265071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Denosumab on Bone Metabolic Markers and Bone Mineral Density in Patients Treated with Glucocorticoids.
    Sawamura M; Komatsuda A; Togashi M; Wakui H; Takahashi N
    Intern Med; 2017; 56(6):631-636. PubMed ID: 28321061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of previous treatment with bisphosphonate and renal impairment on the response to denosumab in osteoporosis: a 'real-life' study.
    Fraser TR; Flogaitis I; Moore AE; Hampson G
    J Endocrinol Invest; 2020 Apr; 43(4):469-475. PubMed ID: 31664706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
    Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
    J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
    Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of daily teriparatide treatment in elderly patients over 80 years of age.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
    Osteoporos Int; 2016 May; 27(5):1869-74. PubMed ID: 26759334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab.
    Miyazawa Y; Sekine Y; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
    Anticancer Res; 2017 Jul; 37(7):3667-3671. PubMed ID: 28668858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
    Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M
    J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients.
    Suzuki T; Nakamura Y; Kato H
    Nutrients; 2017 Aug; 9(8):. PubMed ID: 28805705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: a systematic review and meta-analysis.
    Thongprayoon C; Acharya P; Aeddula NR; Torres-Ortiz A; Bathini T; Sharma K; Ungprasert P; Watthanasuntorn K; Suarez MLG; Salim SA; Kaewput W; Chenbhanich J; Mao MA; Cheungpasitporn W
    Arch Osteoporos; 2019 Mar; 14(1):35. PubMed ID: 30852679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.
    Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2016 Jan; 27(1):405-10. PubMed ID: 26423406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aged-Related Changes in Body Composition and Association between Body Composition with Bone Mass Density by Body Mass Index in Chinese Han Men over 50-year-old.
    Jiang Y; Zhang Y; Jin M; Gu Z; Pei Y; Meng P
    PLoS One; 2015; 10(6):e0130400. PubMed ID: 26090818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experience in using Prolia in patients with postmenopausal osteoporosis in clinical practice].
    Skripnikova IA; Kosmatova OV; Abirova ES; Novikov VE; Murashko LM
    Ter Arkh; 2017; 89(12. Vyp. 2):190-196. PubMed ID: 29488480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in bone mineral density (BMD): a longitudinal study of osteoporosis patients in the real-world setting.
    Berry SD; Dufour AB; Travison TG; Zhu H; Yehoshua A; Barron R; Recknor C; Samelson EJ
    Arch Osteoporos; 2018 Nov; 13(1):124. PubMed ID: 30421141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can lumbar spine bone mineral density predict readmission in denosumab-treated patients with chronic kidney disease?
    Cheng BC; Chen YC
    J Investig Med; 2017 Jan; 65(1):53-56. PubMed ID: 27581054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.